297 related articles for article (PubMed ID: 25200980)
1. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin.
Zhang Y; Ho A; Yue J; Kong L; Zhou Z; Wu X; Yang F; Liang H
Eur J Med Chem; 2014 Oct; 86():449-55. PubMed ID: 25200980
[TBL] [Abstract][Full Text] [Related]
2. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
[TBL] [Abstract][Full Text] [Related]
3. Binding and Anticancer Properties of Plumbagin with Human Serum Albumin.
Gou Y; Zhang Y; Qi J; Kong L; Zhou Z; Liang S; Yang F; Liang H
Chem Biol Drug Des; 2015 Sep; 86(3):362-9. PubMed ID: 25534036
[TBL] [Abstract][Full Text] [Related]
4. Developing Anticancer Ferric Prodrugs Based on the N-Donor Residues of Human Serum Albumin Carrier IIA Subdomain.
Qi J; Gou Y; Zhang Y; Yang K; Chen S; Liu L; Wu X; Wang T; Zhang W; Yang F
J Med Chem; 2016 Aug; 59(16):7497-511. PubMed ID: 27441502
[TBL] [Abstract][Full Text] [Related]
5. Developing an anticancer copper(II) pro-drug based on the nature of cancer cell and human serum albumin carrier IIA subdomain: mouse model of breast cancer.
Gou Y; Zhang Y; Qi J; Chen S; Zhou Z; Wu X; Liang H; Yang F
Oncotarget; 2016 Oct; 7(41):67004-67019. PubMed ID: 27564255
[TBL] [Abstract][Full Text] [Related]
6. Design an anticancer copper(II) pro-drug based on the flexible IIA subdomain of human serum albumin.
Zhang Y; Zhang Z; Gou Y; Jiang M; Khan H; Zhou Z; Liang H; Yang F
J Inorg Biochem; 2017 Jul; 172():1-8. PubMed ID: 28395195
[TBL] [Abstract][Full Text] [Related]
7. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium(II) molecular "light switch" complexes.
Shobha Devi C; Anil Kumar D; Singh SS; Gabra N; Deepika N; Kumar YP; Satyanarayana S
Eur J Med Chem; 2013 Jun; 64():410-21. PubMed ID: 23665797
[TBL] [Abstract][Full Text] [Related]
9. Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain.
Gou Y; Qi J; Ajayi JP; Zhang Y; Zhou Z; Wu X; Yang F; Liang H
Mol Pharm; 2015 Oct; 12(10):3597-609. PubMed ID: 26354410
[TBL] [Abstract][Full Text] [Related]
10. Water-soluble DNA minor groove binders as potential chemotherapeutic agents: synthesis, characterization, DNA binding and cleavage, antioxidation, cytotoxicity and HSA interactions.
Fu XB; Liu DD; Lin Y; Hu W; Mao ZW; Le XY
Dalton Trans; 2014 Jun; 43(23):8721-37. PubMed ID: 24770345
[TBL] [Abstract][Full Text] [Related]
11. Arene ruthenium complexes as anticancer agents.
Süss-Fink G
Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
[TBL] [Abstract][Full Text] [Related]
12. Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity.
Ji L; Zheng W; Lin Y; Wang X; Lü S; Hao X; Luo Q; Li X; Yang L; Wang F
Eur J Med Chem; 2014 Apr; 77():110-20. PubMed ID: 24631730
[TBL] [Abstract][Full Text] [Related]
13. Interaction of ferrocene appended Ru(II), Rh(III) and Ir(III) dipyrrinato complexes with DNA/protein, molecular docking and antitumor activity.
Paitandi RP; Gupta RK; Singh RS; Sharma G; Koch B; Pandey DS
Eur J Med Chem; 2014 Sep; 84():17-29. PubMed ID: 25014746
[TBL] [Abstract][Full Text] [Related]
14. Human topoisomerase inhibition and DNA/BSA binding of Ru(II)-SCAR complexes as potential anticancer candidates for oral application.
De Grandis RA; de Camargo MS; da Silva MM; Lopes ÉO; Padilha EC; Resende FA; Peccinini RG; Pavan FR; Desideri A; Batista AA; Varanda EA
Biometals; 2017 Jun; 30(3):321-334. PubMed ID: 28303361
[TBL] [Abstract][Full Text] [Related]
15. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
Ruiz J; Vicente C; de Haro C; Bautista D
Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of interactions between platinum-/ruthenium-based anticancer agents and human serum albumin: development of HSA carrier for metal-based drugs.
Gou Y; Zhang Y; Yang F; Liang H
Curr Pharm Des; 2015; 21(14):1848-61. PubMed ID: 25732554
[TBL] [Abstract][Full Text] [Related]
17. Half-Sandwich Iridium and Ruthenium Complexes: Effective Tracking in Cells and Anticancer Studies.
Li J; Guo L; Tian Z; Zhang S; Xu Z; Han Y; Li R; Li Y; Liu Z
Inorg Chem; 2018 Nov; 57(21):13552-13563. PubMed ID: 30289251
[TBL] [Abstract][Full Text] [Related]
18. Solvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release.
Jayanthi E; Kalaiselvi S; Padma VV; Bhuvanesh NS; Dharmaraj N
Dalton Trans; 2016 Jan; 45(4):1693-707. PubMed ID: 26699435
[TBL] [Abstract][Full Text] [Related]
19. Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis.
Zheng W; Luo Q; Lin Y; Zhao Y; Wang X; Du Z; Hao X; Yu Y; Lü S; Ji L; Li X; Yang L; Wang F
Chem Commun (Camb); 2013 Nov; 49(87):10224-6. PubMed ID: 23856988
[TBL] [Abstract][Full Text] [Related]
20. Spectroscopic investigation and in vitro cytotoxic activity toward HepG2 cells of a copper compound complexed with human serum albumin.
Li M; Huang S; Cai Q; Xie Y
Luminescence; 2017 Aug; 32(5):888-898. PubMed ID: 28371207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
